Adenoviral Vector-Based Vaccine Platform for COVID-19: Current Status

Overview

Journal Vaccines (Basel)

Date 2023 Feb 28

PMID 36851309

Authors

Vivek P Chavda

Rajashri Bezbaruah

Disha Valu

Bindra Patel

Anup Kumar

Sanjay Prasad

Bibhuti Bhusan Kakoti

Ajeet Kaushik

Mariya Jesawadawala

Affiliations

Soon will be listed here.

Abstract

The coronavirus disease (COVID-19) breakout had an unimaginable worldwide effect in the 21st century, claiming millions of lives and putting a huge burden on the global economy. The potential developments in vaccine technologies following the determination of the genetic sequence of SARS-CoV-2 and the increasing global efforts to bring potential vaccines and therapeutics into the market for emergency use have provided a small bright spot to this tragic event. Several intriguing vaccine candidates have been developed using recombinant technology, genetic engineering, and other vaccine development technologies. In the last decade, a vast amount of the vaccine development process has diversified towards the usage of viral vector-based vaccines. The immune response elicited by such vaccines is comparatively higher than other approved vaccine candidates that require a booster dose to provide sufficient immune protection. The non-replicating adenoviral vectors are promising vaccine carriers for infectious diseases due to better yield, cGMP-friendly manufacturing processes, safety, better efficacy, manageable shipping, and storage procedures. As of April 2022, the WHO has approved a total of 10 vaccines around the world for COVID-19 (33 vaccines approved by at least one country), among which three candidates are adenoviral vector-based vaccines. This review sheds light on the developmental summary of all the adenoviral vector-based vaccines that are under emergency use authorization (EUA) or in the different stages of development for COVID-19 management.

Citing Articles

Sequences in the Cytoplasmic Tail Contribute to the Intracellular Trafficking and the Cell Surface Localization of SARS-CoV-2 Spike Protein.

Burkova E, Bakhno I Biomolecules. 2025; 15(2).

PMID: 40001583 PMC: 11853650. DOI: 10.3390/biom15020280.

Antibody Avidity Maturation Following Booster Vaccination with an Intranasal Adenovirus Salnavac Vaccine.

Astakhova E, Baranov K, Shilova N, Polyakova S, Zuev E, Poteryaev D Vaccines (Basel). 2025; 12(12.

PMID: 39772024 PMC: 11680177. DOI: 10.3390/vaccines12121362.

Adenoviral Vectors for Gene Therapy of Hereditary Diseases.

Muravyeva A, Smirnikhina S Biology (Basel). 2025; 13(12.

PMID: 39765719 PMC: 11673936. DOI: 10.3390/biology13121052.

Mucosal SARS-CoV-2 S1 adenovirus-based vaccine elicits robust systemic and mucosal immunity and protects against disease in animals.

Aljehani N, Tamming L, Khan M, Abdulal R, Alfaleh M, Ghazwani A mBio. 2024; 16(1):e0217024.

PMID: 39629990 PMC: 11708039. DOI: 10.1128/mbio.02170-24.

Role of homologous recombination/recombineering on human adenovirus genome engineering: Not the only but the most competent solution.

Dawson L, Alshawabkeh M, Schroer K, Arakrak F, Ehrhardt A, Zhang W Eng Microbiol. 2024; 4(1):100140.

PMID: 39628785 PMC: 11611009. DOI: 10.1016/j.engmic.2024.100140.

References

Chavda V, Apostolopoulos V . Omicron variant (B.1.1.529) of SARS-CoV-2: Threat for the elderly?. Maturitas. 2022; 158:78-81. PMC: 8799452. DOI: 10.1016/j.maturitas.2022.01.011. View

Reche P . Potential Cross-Reactive Immunity to SARS-CoV-2 From Common Human Pathogens and Vaccines. Front Immunol. 2020; 11:586984. PMC: 7596387. DOI: 10.3389/fimmu.2020.586984. View

Chavda V, Vuppu S, Mishra T, Kamaraj S, Patel A, Sharma N . Recent review of COVID-19 management: diagnosis, treatment and vaccination. Pharmacol Rep. 2022; 74(6):1120-1148. PMC: 9549062. DOI: 10.1007/s43440-022-00425-5. View

Sailaja G, HogenEsch H, North A, Hays J, Mittal S . Encapsulation of recombinant adenovirus into alginate microspheres circumvents vector-specific immune response. Gene Ther. 2002; 9(24):1722-9. PMC: 1459421. DOI: 10.1038/sj.gt.3301858. View

Dutta N, Mazumdar K, Gordy J . The Nucleocapsid Protein of SARS-CoV-2: a Target for Vaccine Development. J Virol. 2020; 94(13). PMC: 7307180. DOI: 10.1128/JVI.00647-20. View

Wrapp D, Wang N, Corbett K, Goldsmith J, Hsieh C, Abiona O . Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020; 367(6483):1260-1263. PMC: 7164637. DOI: 10.1126/science.abb2507. View

Moller J, Kraner M, Sonnewald U, Sangal V, Tittlbach H, Winkler J . Proteomics of diphtheria toxoid vaccines reveals multiple proteins that are immunogenic and may contribute to protection of humans against Corynebacterium diphtheriae. Vaccine. 2019; 37(23):3061-3070. DOI: 10.1016/j.vaccine.2019.04.059. View

Lurie N, Saville M, Hatchett R, Halton J . Developing Covid-19 Vaccines at Pandemic Speed. N Engl J Med. 2020; 382(21):1969-1973. DOI: 10.1056/NEJMp2005630. View

Tenforde M, Olson S, Self W, Talbot H, Lindsell C, Steingrub J . Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years - United States, January-March 2021. MMWR Morb Mortal Wkly Rep. 2021; 70(18):674-679. PMC: 9368749. DOI: 10.15585/mmwr.mm7018e1. View

10.

Ritter T, Lehmann M, Volk H . Improvements in gene therapy: averting the immune response to adenoviral vectors. BioDrugs. 2002; 16(1):3-10. DOI: 10.2165/00063030-200216010-00001. View

11.

Dangi T, Sanchez S, Lew M, Awakoaiye B, Visvabharathy L, Richner J . Pre-existing immunity modulates responses to mRNA boosters. Cell Rep. 2023; 42(3):112167. PMC: 9928730. DOI: 10.1016/j.celrep.2023.112167. View

12.

Zhang P, Miao D, Zhang Y, Wang M, Hu Z, Lu P . Cloning and rescue of the genome of Bombyx mori bidensovirus, and characterization of a recombinant virus. Virol J. 2016; 13:126. PMC: 4938981. DOI: 10.1186/s12985-016-0576-5. View

13.

Chavda V, Bezbaruah R, Athalye M, Parikh P, Chhipa A, Patel S . Replicating Viral Vector-Based Vaccines for COVID-19: Potential Avenue in Vaccination Arena. Viruses. 2022; 14(4). PMC: 9025561. DOI: 10.3390/v14040759. View

14.

Ramsauer K, Schwameis M, Firbas C, Mullner M, Putnak R, Thomas S . Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial. Lancet Infect Dis. 2015; 15(5):519-27. DOI: 10.1016/S1473-3099(15)70043-5. View

15.

Munro A, Janani L, Cornelius V, Aley P, Babbage G, Baxter D . Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021; 398(10318):2258-2276. PMC: 8639161. DOI: 10.1016/S0140-6736(21)02717-3. View

16.

Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y . Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B. 2020; 10(5):766-788. PMC: 7102550. DOI: 10.1016/j.apsb.2020.02.008. View

17.

Pishesha N, Harmand T, Rothlauf P, Praest P, Alexander R, van den Doel R . A class II MHC-targeted vaccine elicits immunity against SARS-CoV-2 and its variants. Proc Natl Acad Sci U S A. 2021; 118(44). PMC: 8612213. DOI: 10.1073/pnas.2116147118. View

18.

Alba R, Bosch A, Chillon M . Gutless adenovirus: last-generation adenovirus for gene therapy. Gene Ther. 2005; 12 Suppl 1:S18-27. DOI: 10.1038/sj.gt.3302612. View

19.

Ong E, Wong M, Huffman A, He Y . COVID-19 Coronavirus Vaccine Design Using Reverse Vaccinology and Machine Learning. Front Immunol. 2020; 11:1581. PMC: 7350702. DOI: 10.3389/fimmu.2020.01581. View

20.

Feng L, Wang Q, Shan C, Yang C, Feng Y, Wu J . An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques. Nat Commun. 2020; 11(1):4207. PMC: 7442803. DOI: 10.1038/s41467-020-18077-5. View